Retatrutide is marginally more likely to cause each listed side effect, but we are talking 1 to 3 percentage point gaps across the board
This is your time to ask questions, discuss your goals, and get an overall understanding of the medication
Lin H, Prather C, Fisher R, et al
Lack of clinical data: There is limited research on the effects of splitting semaglutide doses, making it difficult to predict long-term outcomes
This trial aims to investigate whether retatrutide may positively impact cardiovascular health and reduce the risk of events [29]
In 2021, it became the first drug (marketed under the brand name Wegovy) since 2014s Saxenda approved for chronic weight management in the 70% of American adults who are overweight or obese